Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms FY2026 Sales Guidance

    Question

    Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms FY2026 Sales Guidance

    Direct answer

    Dentsply Sirona delivered second-quarter adjusted EPS of $0.52, coming in ahead of the $0.36 Wall Street consensus. Top-line revenue contracted 4.1% relative to the prior-year period. Performance varied across divisions, with Wellspect Healthcare delivering 7.1% growth. Management maintained full-year 2026 guidance for revenue of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms FY2026 Sales Guidance”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-beats-q2-eps-at-0-52-and-affirms-fy2026-sales-guidance-1b7d36

    EQUITY
    Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms FY2026 Sales Guidance
    Dentsply Sirona delivered second-quarter adjusted EPS of $0.52, coming in ahead of the $0.36 Wall Street consensus. Top-line revenue contracted 4.1% relative to the prior-year period. Performance varied across divisions, with Wellspect Healthcare delivering 7.1% growth. Management maintained full-year 2026 guidance for revenue of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.
    XRAYALGN
    Impact
    68
    SEP 9
    SIG
    88%
    XRAYALGN
    Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms FY2026 Sales Guidance
    Dentsply Sirona delivered second-quarter adjusted EPS of $0.52, coming in ahead of the $0.36 Wall Street consensus. Top-line revenue contracted 4.1% relative to the prior-year period. Performance varied across divisions, with Wellspect Healthcare delivering 7.1% growth. Management maintained full-year 2026 guidance for revenue of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.
    → Dental consumable volume declines pressure top-line revenue while operational cost control supports XRAY adjusted EPS toward the $1.40 to $1.50 annual target.
    Impact
    Dentsply Sirona delivered second-quarter adjusted EPS of $0.52, coming in ahead of the $0.36 Wall Street consensus. Top-line revenue contracted 4.1% relative to the prior-year period. Performance varied across divisions, with Wellspect Healthcare delivering 7.1% growth. Management maintained full-year 2026 guidance for revenue of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.
    Affected
    XRAYALGN
    Transmission
    Dental consumable volume declines pressure top-line revenue while operational cost control supports XRAY adjusted EPS toward the $1.40 to $1.50 annual target.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYcost-control pass-through to operating earnings against top-line contractionMixed1-5dReported Q2 adjusted EPS of $0.52 vs $0.36 consensus with revenues down 4.1% YoY.
    ALGNpeer dental equipment demand read-acrossWatch1-4wMentioned as dental sector peer facing similar end-market demand dynamics.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYMixed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month